ReCode Therapeutics

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a selective organ targeting (SORT) lipid nanoparticle platform that facilitates the precise delivery of genetic therapies and proteins to specific organs and tissues, extending beyond traditional liver-targeted approaches. This innovative technology aims to address the limitations of existing gene therapy methods and provide effective solutions for patients suffering from rare and life-limiting respiratory diseases. Through its efforts, ReCode Therapeutics seeks to transform the treatment landscape for individuals impacted by genetic disorders.